VacZine Analytics  
MarketVIEW: Periodontal P.gingivalis vaccines

Published: September 2019

Periodontal disease or 'gum disease' is a hugely prevalent inflammatory condition in adults affecting around two-thirds of the world population (mild/moderate and severe disease). The disease has become a global health concern and exerts substantial economic burden on healthcare systems due to the cost of mechanical surgical, dental treatment.

The bacterium Porphyromonas gingivalis (P. gingivalis) has been identified as a 'keystone' dysbiotic pathogen in periodontitis which causes impaired immunity through its interaction with the host complement system. The bacterium has a high prevalence in periodontitis patients and an association with alveolar bone loss. Research studies have demonstrated that specific blocking of P. gingivalis can reverse dysbiotic effects and protect against periodontal disease indictors, thereby implicating this mechanism as a potential therapy. In addition to its involvement in periodontal diseases, P. gingivalis also has a demonstrated association with many other chronic diseases such as cardiovascular, kidney, metabolic, respiratory disorders, cancer and has even more recently been implicated in Alzheimer's disease. Evidence for its association and potential involvement in the pathogenesis of these additional chronic conditions is further strengthening a hypothesis for its selective targeting with a therapeutic small molecule or vaccine.

This MarketVIEW contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of P. gingivalis vaccines across Western economies until 2040. The model contains value ($ m) and volume (million doses) predictions for an example vaccine-targeted segment along with timeframe, pricing and penetration estimates. The product also includes an in-depth review of periodontitis disease, epidemiology, treatments/guidelines and most recent developments in R&D (academic and commercial). It is an ideal “first pass” look at this intriguing vaccine opportunity. THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV083 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains